Eli Lilly (LLY) stock is trading near its all-time highs, with the shares only about 5% away from the record levels set in ...

In 2Q 2024, Eli Lilly and Company (NYSE:LLY)’s revenue went up by 36% as a result of Mounjaro, Zepbound, and Verzenio. When $579.0 million of revenue from the sale of rights for Baqsimi in 2Q ...

Barron’s 2024 Healthcare Roundtable panelists make the case for 21 healthcare companies of all stripes, including Humana, Novo Nordisk, BioLife Solutions, and more.

This is also why LLY does not appear to be expensive at current levels, with the FWD PEG non-GAAP ratio of 1.30x, well below its historical levels and sector peers. It goes without saying that the ...

Investors in Eli Lilly (Symbol: LLY) saw new options become available today, for the April 2025 expiration. One of the key inputs that goes into the price an option buyer is willing to pay ...

Eli Lilly and Company (NYSE: LLY) announced these new long-term results from the ADjoin long-term extension study, which will be presented at the European Academy of Dermatology and Venereology ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Bank of America Securities analyst Alec Stranahan maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today. The company’s shares closed yesterday at $935.02. According to ...

In this article, we will have a look at where Eli Lilly and Company (NYSE:LLY) ranks among other unstoppable dividend stocks to buy. It’s undeniable that dividends have played a key role in the ...

Below is Validea's guru fundamental report for ELI LILLY AND CO (LLY). Of the 22 guru strategies we follow, LLY rates highest using our P/B Growth Investor model based on the published strategy of ...

Eli Lilly’s (LLY) second-quarter 2024 financial results ... If you exclude the $579 million from the sale of Baqsimi rights ...